Please use this identifier to cite or link to this item:
|Title:||Management of leptomeningeal metastasis in breast cancer||Authors:||Assi, Hazem I
Saadeh, Fadi S
El Darsa, Haidar
|Affiliations:||Faculty of Medicine||Keywords:||Brain cancer
|Issue Date:||2018||Publisher:||Elsevier||Part of:||Clinical Neurology and Neurosurgery||Volume:||172||Start page:||151||End page:||159||Abstract:||
Leptomeningeal metastasis (LM), which occurs when malignant cells spread to the central nervous system, is becoming an increasingly common complication in patients with breast cancer. Diagnosis and treatment of LM is challenging. Moreover, prognosis of patients with LM is poor, with a median survival of 6 months after diagnosis. This review highlights the strengths and limitations of currently available diagnostic tools and therapies for LM. The current treatments for LM, including radiotherapy, systemic therapy, and intrathecal treatment, aim to maintain the quality of life of patients by correcting neurological deficits and arresting neurological degeneration. However, there is no standardized therapy for LM because of a lack of randomized trials on this condition.
|URI:||https://scholarhub.balamand.edu.lb/handle/uob/5709||ISSN:||03038467||DOI:||10.1016/j.clineuro.2018.07.001||Ezproxy URL:||Link to full text||Type:||Journal Article|
|Appears in Collections:||Faculty of Medicine|
Show full item record
checked on Jul 2, 2022
checked on Jul 3, 2022
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.